Strategic build-up of robust pipeline
  • Immune checkpoint inhibitors (ICI) are generally expensive. Moreover, the patient response rate is only 20~30%. The small-molecule drugs can be attractive combination partners for the ICIs that overcome such limits and provide a novel direction for the field of combination drug design.
  • Therapex develops small molecule anti-cancer drugs that are effective for advanced refractory solid tumors along with ICIs. One of the pivotal roles of these IO drugs is to inhibit the ability of tumor microenvironment to evade the immune response. The clinical development of IBC-1131 will hugely contribute to maximizing the efficacy of the immuno-oncology therapy and thus benefiting the patients to reduce the medical costs.
Mechanism of Immuno-Oncology
면역항암제 적용사례